 | Up a level |
Giudici, F; Bertisch, B; Negro, F; Stirnimann, G; Müllhaupt, B; Moradpour, D; Cerny, A; Dufour, Jean-François; Keiser, O (2016). Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. Journal of viral hepatitis, 23(9), pp. 697-707. Blackwell Science 10.1111/jvh.12535
Rüeger, S; Bochud, P-Y; Dufour, Jean-François; Müllhaupt, B; Semela, D; Heim, M H; Moradpour, D; Cerny, A; Malinverni, R; Booth, D R; Suppiah, V; George, J; Argiro, L; Halfon, P; Bourlière, M; Talal, A H; Jacobson, I M; Patin, E; Nalpas, B; Poynard, T; ... (2014). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), pp. 1605-1615. BMJ Publishing Group 10.1136/gutjnl-2014-306997
Girardin, F; Daali, Y; Gex-Fabry, M; Rebsamen, M; Roux-Lombard, P; Cerny, A; Bihl, F; Binek, J; Moradpour, D; Negro, F; Desmeules, J; Swiss Hepatitis C Cohort Study Group, (2012). Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. Journal of viral hepatitis, 19(8), pp. 568-73. Oxford: Blackwell Science 10.1111/j.1365-2893.2011.01578.x
Frei, P; Leucht, AK; Held, U; Kofmehl, R; Schmitt, J; Rau, M; Gerlach, T; Negro, F; Heim, MH; Moradpour, D; Cerny, A; Dufour, Jean-François; Mullhaupt, B; Geier, A (2011). Age Above 60 Years Is Not a Negative Predictive Factor For Combined Antiviral Therapy With Pegylated Interferon Alpha and Ribavirin in Hepatitis C Patients. Hepatology, 54(1), 826A-826A. Hoboken, N.J.: Wiley Interscience
Lange, CM; Bibert, S; Kutalik, Z; Morikawa, K; Cerny, A; Dufour, Jean-François; Gerlach, TJ; Heim, MH; Malinverni, R; Muellhaupt, B; Negro, F; Badenhoop, K; Sarrazin, C; Berg, T; Gouttenoire, J; Bochud, PY; Moradpour, D (2011). Swiss Hepatitis C Cohort Study. A Large Scale Genetic Validation Study Coupled With In-Vitro Analysis Reveal a Role of Vitamin D-Signaling in the Pathogenesis and Treatment of Chronic Hepatitis C. Hepatology, 54(1), p. 537. Hoboken, N.J.: Wiley Interscience 10.1016/S0168-8278(11)61359-7
Bochud, PY; Bibert, S; Kutalik, Z; Patin, E; Guergnon, J; Nalpas, B; Goossens, N; Kuske, L; Müllhaup, B; Gerlach, T; Heim, MH; Moradpour, D; Cerny, A; Malinverni, R; Regenass, S; Dollenmaier, G; Hirsch, H; Martinetti, G; Gorgiewski, M; Boulière, M; ... (2011). Swiss Hepatitis C Cohort Study Grp. IL28B Polymorphisms Linked to Poor Response To Treatment are Associated with Low Necroinflammatory Activity and Slow Fibrosis Progression in HCV Genotype Non-1-Infected patientsBern. Hepatology, 54(1), p. 539. Hoboken, N.J.: Wiley Interscience 10.1016/S0168-8278(11)61363-9
Lange, CM; Kutalik, Z; Morikawa, K; Bibert, S; Cerny, A; Dollenmaier, G; Dufour, Jean-François; Gerlach, TJ; Heim, MH; Malinverni, R; Müllhaupt, B; Negro, F; Moradpour, D; Bochud, PY (2011). the Swiss Hepatitis C Cohort Study Group. Hepatology Hoboken, N.J.: Wiley Interscience
Overbeck, K; Dufour, Jean-François; Müllhaupt, B; Helbling, B; Borovicka, J; Malinverni, R; Heim, M; Moradpur, D; Cerny, A; Rickenbach, M; Negro, F (2010). Impact of international consensus guidelines on atniviral therapy of chronic hepatitis C patients in Switzerland. Swiss medical weekly Muttenz: EMH Schweizerischer Ärzteverlag
Sgier, C; Müllhaupt, B; Gerlach, T; Moradpour, D; Negro, F; Malé, PJ; Heim, MH; Malinverni, R; Cerny, A (2010). Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. Journal of viral hepatitis, 17(12), pp. 845-850. Oxford: Blackwell Science 10.1111/j.1365-2893.2009.01251.x
Helbling, B; Overbeck, K; Gonvers, J-J; Malinverni, R; Dufour, Jean-François; Borovicka, J; Heim, M; Cerny, A; Negro, F; Bucher, S; Rickenbach, M; Renner, E L; Mullhaupt, B (2008). Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut, 57(11), pp. 1597-603. London: BMJ Publishing Group 10.1136/gut.2007.142844
Dufour, Jean-François; Oneta, CM; Gonvers, JJ; Bihl, F; Cerny, A; Cereda, JM; Zala, JF; Helbling, B; Steuerwald, M; Zimmermann, A; Swiss, Association for the Study of the Liver (2006). Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clinical gastroenterology and hepatology, 4(12), pp. 1537-43. Philadelphia, Pa.: Elsevier 10.1016/j.cgh.2006.09.025
Helbling, B; Jochum, W; Stamenic, I; Knöpfli, M; Cerny, A; Borovicka, J; Gonvers, JJ; Wilhelmi, M; Dinges, S; Müllhaupt, B; Esteban, A; Meyer-Wyss, B; Renner, EL; Swiss, Association for the Study of the Liver (SASL) (2006). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. Journal of viral hepatitis, 13(11), pp. 762-9. Oxford: Blackwell Science 10.1111/j.1365-2893.2006.00753.x
Pfister, M; Gottstein, Bruno; Kretschmer, Robert; Cerny, T; Cerny, A (2001). Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. Clinical chemistry and laboratory medicine, 39(6), pp. 527-530. Walter de Gruyter 10.1515/CCLM.2001.088
